Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts

Cancer Chemotherapy and Pharmacology

Volumn 48, Issue 4, 2001, Pages 319-326

  Newman, R A ^a   Yang, J ^a   Finla, M R V ^a   Cabral, F ^a   Vourloumis, D ^a   Stephens, L C ^a   Troncoso, P ^a   Wu, X ^a   Logothetis, C J ^a   Nicolaou, K C ^a   Navone, N M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Drug development; Epothilone; Paclitaxel; Prostate cancer

Indexed keywords

26 FLUOROEPOTHILONE B; CGP 85715; EPOTHILONE A; EPOTHILONE B; EPOTHILONE DERIVATIVE; MUTANT PROTEIN; PACLITAXEL; SODIUM CHLORIDE; TAX PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL MUTANT; CHO CELL; COMPARATIVE TOXICOLOGY; CONTROLLED STUDY; CYTOTOXICITY TEST; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; MALE; MAXIMUM TOLERATED DOSE; MICROTUBULE ASSEMBLY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CARCINOMA; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; EPOTHILONES; HUMANS; INFUSIONS, INTRAVENOUS; MACROLIDES; MALE; MICE; MICE, NUDE; PACLITAXEL; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 17944378190     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800100323     Document Type: Article

References (29)

1. Epothilones and related structures - A new class of microtubule inhibitors with potent antitumor activity
2. Epothilones, a new class of microtubule stabilizing agents with a Taxol-like mechanism of action
3. Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of Taxol for cell division
4. CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin
5. A mechanism of cellular resistance to drugs that interfere with microtubule assembly
6. Management of cancer of the prostate
7. Desoxyepothilone B: An efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B
8. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel
9. Events in the natural history of prostate cancer using salvage curves, mean age distributions and contingency coefficients
10. Mechanistic concepts in androgen-dependence of prostate cancer
11. Epothilones A and B - Antifungal activity and cytotoxic compound from Sorangium cellulosum (Myxobacteria) - Production, physicochemical and biological properties
12. A common pharmacophore for epothilone and taxanes: Molecular basis for drug resistance conferred by tubulin mutations in human cancer cells
13. Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts
14. Activities of the microtubule-stabilizing agents epothilones A and B and purified tubulin and in cells resistant to paclitaxel (Taxol)
15. The biochemical pharmacology of Taxol and mechanisms of resistance
16. Apoptosis in murine tumors treated with chemotherapy agents
17. Relation of apoptosis to cancer therapy
18. Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors treated with taxol
19. Epothilone B stabilizes microtubuli of macrophages like taxol without showing taxol-like endotoxin activity
20. Establishment of two human prostate cancer cell lines derived from a single bone metastasis
21. Model systems of prostate cancer: Uses and limitations
22. TabBO: A model reflecting common molecular features of androgen-independent prostate cancer
23. Chemical biology of epothilones
24. A common pharmacophore for cytotoxic natural products that stabilize microtubules
25. Early detection of prostate cancer
26. Hormone-refractory (D3) prostate cancer: Refining the concept
27. Promotion of microtubule assembly in vitro by taxol
28. Apoptotic and mitotic indices predict patient survival rates in lymph node-negative colon carcinomas
29. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer